UCB, Biogen lupus drug scores in phase 3 trial

UCB, Biogen lupus drug scores in phase 3 trial

Source: 
Pharmaphorum
snippet: 

UCB and Biogen say their first phase 3 trial of their systemic lupus erythematosus (SLE) candidate dapirolizumab pegol was a success, and a second is now expected to start before the end of the year.